Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay

Li, Xiaolei; Liu, Junyan; Lü, Rong; Xu, Qiong; Zhu, Zhifeng; Wang, Li; Zhou, Chunlei; Jia, Jing; Fu, Zheng; Yao, Zhi

doi:10.1007/s10637-008-9121-8

Cited by 10 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al. used HFA to test the therapeutic efficacy of tripeptide tyroserleutide (YSL) in five different human HCC‐cell lines (Li et al. 2008).…”

Section: Xenograft Modelsmentioning

confidence: 99%

“…The ability for multiplexing reduces the number of laboratory animals; this combined with the shorter evaluation time and reduced consumption of test agents makes it an economically interesting method . Li et al used HFA to test the therapeutic efficacy of tripeptide tyroserleutide (YSL) in five different human HCC-cell lines (Li et al 2008). The mice were implanted with three hollow fibres containing BEL-7402, SMMC-7721 and Hep3B or two hollow fibres with HepG2 and SK-HEP-1, and were treated with YSL.…”

Section: Xenograft Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Experimental mouse models for hepatocellular carcinoma research

Heindryckx

Colle

Vlierberghe

2009

Int J Experimental Path

317

342

View full text Add to dashboard Cite

Every year almost 500,000 new patients are diagnosed with hepatocellular carcinoma (HCC), a primary malignancy of the liver that is associated with a poor prognosis. Numerous experimental models have been developed to define the pathogenesis of HCC and to test novel drug candidates. This review analyses several mouse models useful for HCC research and points out their advantages and weaknesses. Chemically induced HCC mice models mimic the injury-fibrosis-malignancy cycle by administration of a genotoxic compound alone or, if necessary, followed by a promoting agent. Xenograft models develop HCC by implanting hepatoma cell lines in mice, either ectopically or orthotopically; these models are suitable for drug screening, although extrapolation should be considered with caution as multiple cell lines must always be used. The hollow fibre assay offers a solution for limiting the number of test animals in xenograft research because of the ability for implanting multiple cell lines in one mouse. There is also a broad range of genetically modified mice engineered to investigate the pathophysiology of HCC. Transgenic mice expressing viral genes, oncogenes and/or growth factors allow the identification of pathways involved in hepatocarcinogenesis

show abstract

“…Li et al. used HFA to test the therapeutic efficacy of tripeptide tyroserleutide (YSL) in five different human HCC‐cell lines (Li et al. 2008).…”

Section: Xenograft Modelsmentioning

confidence: 99%

Section: Xenograft Modelsmentioning

confidence: 99%

Experimental mouse models for hepatocellular carcinoma research

Heindryckx

Colle

Vlierberghe

2009

Int J Experimental Path

317

342

View full text Add to dashboard Cite

show abstract

“…Because HFA can provide the real in vivo environment,in accordance with the action characteristics of natural products involving traditional Chinese herbs, HFA has potential broad application prospects in antitumor research field of traditional Chinese herbs and other natural products [3]. Moreover, a large number of research results showed that HFA was also an effective method to quickly research pharmacodynamics (e.g., Pervilleines B and C [4], Paclitaxel and Pacliex [5], C1311 and SJG-13 [6], ASI-145 [7], YSL [8], TAS-102 [9]) and mechanism (e.g., PCNA and Rb [10], p16 [11], NF-kappa B [12]) of antitumor drugs.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor pharmacological evaluation of extracts from stellera chamaejasme L based on hollow fiber assay

Liu

Yang

Zhang

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundStellera chamaejasme L, a traditional Chinese herb, has long been used for treatment of various tumors in the Chinese population. In our previous study, we paid an attention to the cytotoxic and proapoptotic effects of Stellera chamaejasme L extracts (ESC, ESC-1 and ESC-2, the latter two were isolated from ESC) on 4 various tumor cells (NCI-H157, NCI-H460, BEL-7402 and SK-HEP-1) in vitro. ESCs showed significantly inhibitory effects on the 4 tumor cells. ESC-2 had the strongest inhibitory effect and the broadest sensitive cell spectrum. ESC-2 and ESC acted in a similar way against tumor cells, which suggested anti-tumor active fraction of ESC might exist in ESC-2. Here, we further observe the inhibitory and proapoptotic effects of Stellera chamaejasme L extracts in vivo.MethodsIn this study, we used hollow fiber tumor model to evaluate the inhibitory and proapoptotic effects of Stellera chamaejasme L extracts. Apoptotic rates of the cancer cells retrieved from the hollow fibers were measured with flow cytometric analysis, caspase 3, 8, 9 enzyme activities were detected by colorimetric assay, Fas, Fas-L, TNF-R1 and TNF-α expression were determined with elisa assay and radioimmunoassay respectively.ResultsThe results showed that ESC, ESC-2 all had inhibitory effects on 4 tumor cells. According to the effect strength, dose and antitumor spectrum, the order of antitumor effects of ESCs was: ESC-2 > ESC > ESC-1. NCI-H460 cells were the most sensitive to ESCs. ESC, ESC-2 increased greatly the apoptotic rate and caspase 3, 8 enzyme activities in NCI-H460. ESCs had no significant effects on expression of Fas, Fas-L protein, but TNF-α/TNFR1 protein expression in NCI-H460 cells changed significantly after ESC and ESC-2 treatment.ConclusionESC-2 had the similar antitumor effect to that of ESC in vivo and further confirmed that ESC-2 may be the main antitumor active fraction of ESC, which was consistent with our previous results in vitro.

show abstract

“…The concentration of nanoparticles was selected by referring to previous studies. 36 After 24 h and 48 h, the washed cells were treated with CCK-8 reagent. Cells that were not treated with NPs were used as a negative controls.…”

Section: Methodsmentioning

confidence: 99%

Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma

Ma¹,

Tiantian²,

Hua³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose Hepatocellular carcinoma (HCC) is a common malignant tumor that seriously threatens human life and health. Currently, the majority of antitumor drugs are administered in an injectable manner, which can cause pain and side effects to patients. Objective of this study is to establish an effective oral drug delivery system for anti hepatoma drugs. Methods In this study, intestinal targeting cell penetrating peptide (R6LRVG) was obtained by binding cell penetrating peptide (R6) with the polypeptide of LRVG (targeting intestinal epithelial cells). Next, R6LRVG-modified tyroserleutide-poly(lactic-co-glycolic acid) (PLGA) nanoparticles (YSL-PLGA/R6LRVG NPs) were prepared. After that, the nanoparticles were characterized and their stability was evaluated. The cellular uptake, in vitro bioactivity and in vivo antitumor activity of the nanoparticles were investigated. In addition, the mechanism, including the endocytic pathway and respiratory rate detection of mitochondria, was further investigated. Results YSL-PLGA/R6LRVG NPs were successfully prepared. Characterization revealed YSL-PLGA/R6LRVG NPs to be globular particles with smooth surfaces and an average diameter of 222.6 nm. The entrapment efficiency and drug loading of tyroserleutide were 70.27% and 19.69%, respectively. Furthermore, the YSL-PLGA/R6LRVG NPs group exhibited the largest amount of YSL uptake. We also found that cell uptake of YSL-PLGA/R6LRVG NPs could be related to the endocytosis pathways mediated by reticulin and caveolae/lipid rafts. Additionally, the YSL-PLGA/R6LRVG NPs could interfere with mitochondrial function. In vivo experiments revealed that orally administered YSL-PLGA/R6LRVG NPs exerted excellent anticancer effects in tumor-bearing mice. Hematoxylin-eosin staining did not show any histological changes in the major organs. Conclusion To summarize, YSL-PLGA/R6LRVG NPs could be a useful oral delivery system of YSL and may provide a new platform for the oral delivery of anticancer drugs.

show abstract

Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay

Cited by 10 publications

References 14 publications

Experimental mouse models for hepatocellular carcinoma research

Experimental mouse models for hepatocellular carcinoma research

Anti-tumor pharmacological evaluation of extracts from stellera chamaejasme L based on hollow fiber assay

Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma

Contact Info

Product

Resources

About